ImmuCell Corporation
ICCC
Rank in Stocks
#19996
ImmuCell Corporation functions as an animal health enterprise, specializing in... ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Share Price
$10.22
Last synced: 2026-11-09
Market Cap
$92.82M
Change (1 day)
4.29%
Change (1 year)
63.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade ImmuCell Corporation (ICCC)
Category
Healthcare
EPS for ImmuCell Corporation (ICCC)
EPS as of June 2026 TTM: $0.08
According to ImmuCell Corporation's latest financial reports, its current EPS (TTM) is $0.08. At the end of 2025 the company had an EPS of $-0.12, an increase over its 2024 EPS of $-0.26.
EPS history for ImmuCell Corporation from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.08 | -170.50% |
| 2025 | $-0.12 | -53.85% |
| 2024 | $-0.26 | -65.33% |
| 2023 | $-0.75 | 134.38% |
| 2022 | $-0.32 | 3,006.80% |
| 2021 | $-0.01 | -92.64% |
| 2020 | $-0.14 | -26.32% |
| 2019 | $-0.19 | -54.76% |
| 2018 | $-0.42 | 1,138.94% |
| 2017 | $-0.03 | -128.25% |
| 2016 | $0.12 | -70.00% |
| 2015 | $0.40 | -824.64% |
| 2014 | $-0.06 | -238.00% |
| 2013 | $0.04 | 33.33% |
| 2012 | $0.03 | -121.43% |
| 2011 | $-0.14 | 7.69% |
| 2010 | $-0.13 | 77.60% |
| 2009 | $-0.07 | -54.25% |
| 2008 | $-0.16 | -169.57% |
| 2007 | $0.23 | 4.55% |
| 2006 | $0.22 | -12.00% |
| 2005 | $0.25 | 400.00% |
| 2004 | $0.05 | -66.67% |
| 2003 | $0.15 | -53.13% |
| 2002 | $0.32 | 113.33% |
| 2001 | $0.15 | -82.14% |
| 2000 | $0.84 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 18,410.64% |
US
|
|
| $-7.07 | -8,456.97% |
US
|
|
| $-5.29 | -6,352.96% |
AU
|
|
| $12.88 | 15,124.70% |
BE
|
|
| $21.56 | 25,384.63% |
NL
|
Questions about ImmuCell Corporation's earnings per share (EPS)
What is ImmuCell Corporation's earnings per share (EPS)?
ImmuCell Corporation's earnings per share (EPS) over the last twelve months is $0.08, as of Jun 2026.
What was ImmuCell Corporation's earnings per share (EPS) in 2025?
In 2025, ImmuCell Corporation's earnings per share (EPS) was $-0.12, compared with $-0.26 in 2024.
How has ImmuCell Corporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, ImmuCell Corporation's earnings per share (EPS) was highest in 2021 ($-0.01) and lowest in 2023 ($-0.75).
How does ImmuCell Corporation's earnings per share (EPS) compare with similar companies?
ImmuCell Corporation's earnings per share (EPS) ($0.08) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.